论文部分内容阅读
目的：观察红细胞生成素（ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ，Ｅｒｙ）治疗非透析或腹膜透析慢性肾功能衰竭贫血病人的疗效和安全性的差别。方法：Ｅｒｙ２５００Ｕ／次，２次／ｗｋ，ｓｃ或３次／ｗｋ，ｉｖ，治疗非透析慢性肾功能衰竭（肾衰）７例病人（Ａ组）与６例腹膜透析慢性肾衰的病人（Ｂ组）作对照。结果：就贫血的改善，对２组均有效，但Ａ组不良反应发生率占６／７（８６％），病情明显加重占３／７（４３％），Ｂ组无１例发生不良反应。结论：Ｅｒｙ用于非透析慢性肾衰病人贫血治疗应持慎重态度。
Objective: To observe the difference of efficacy and safety between erythropoietin (Ery) and non-dialysis or peritoneal dialysis patients with chronic renal failure. Methods: Seven patients with non-dialysis chronic renal failure (group A) and 6 patients with chronic renal failure due to peritoneal dialysis (B group) were treated with Ery2500U / time, twice / wk, sc or three times / Group) as a control. Results: The improvement of anemia was effective in both groups. However, the incidence of adverse reactions in group A accounted for 6/7 (86%), and the condition was significantly increased in 3/7 (43%). No adverse reactions occurred in group B. Conclusion: Ery should be used with caution in the treatment of anemia in patients with chronic renal failure without dialysis.